A 64-year-old female with primarily diagnosed small cell lung cancer was referred to our department for positron emission tomography (PET)/computed tomography work-up with [
Ga]Pentixafor, a radiolabeled, highly human-specific receptor ligand for PET imaging, has been demonstrated in patients with small cell lung cancer and other (hematologic) diseases. 1 Although the feasibility of [
68 Ga] Pentixafor PET imaging has not been studied in experimental models of ischemic stroke yet, the stromal cell-derived factor 1α/ CXC-motif chemokine receptor 4 axis has been shown to play an important role in the recruitment of inflammatory and stem and progenitor cells to the areas of ischemic injury after both myocardial infarction 2 and ischemic stroke. 3, 4 Its noninvasive, in vivo visualization might lead to novel insights into the course and prognostic implications of postischemic inflammatory response.
Disclosures
Dr Wester is the founder and shareholder of Scintomics. S. Kropf is CEO of Scintomics. The other authors report no conflicts. 68 Ga]Pentixafor-PET (one day later) visualizes upregulation of CXCR4 (D, Inset; maximum intensity projection; standardized uptake value max =4.08 versus standardized uptake value mediastinal bloodpool =1.62), which correlates with cMRI changes (E, DWI/PET fusion). CXCR indicates CXC-motif chemokine receptor; DWI, diffusion-weighted image; and PET, positron emission tomography.
